These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31057089)

  • 1. Insights into structural dynamics of allosteric binding sites in HCV RNA-dependent RNA polymerase.
    Mittal L; Kumari A; Suri C; Bhattacharya S; Asthana S
    J Biomol Struct Dyn; 2020 Apr; 38(6):1612-1625. PubMed ID: 31057089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Allosteric Inhibitors Jointly Modulate Protein Structure and Dynamics in the Hepatitis C Virus Polymerase.
    Brown JA; Thorpe IF
    Biochemistry; 2015 Jul; 54(26):4131-41. PubMed ID: 26066778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors.
    Elhefnawi M; ElGamacy M; Fares M
    BMC Bioinformatics; 2012; 13 Suppl 17(Suppl 17):S5. PubMed ID: 23282180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing the "fingers" domain binding pocket of Hepatitis C virus NS5B RdRp and D559G resistance mutation via molecular docking, molecular dynamics simulation and binding free energy calculations.
    Manjula S; Sivanandam M; Kumaradhas P
    J Biomol Struct Dyn; 2019 Jun; 37(9):2440-2456. PubMed ID: 30047829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-nucleoside Inhibitors of Zika Virus RNA-Dependent RNA Polymerase.
    Gharbi-Ayachi A; Santhanakrishnan S; Wong YH; Chan KWK; Tan ST; Bates RW; Vasudevan SG; El Sahili A; Lescar J
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32796069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two RNA Tunnel Inhibitors Bind in Highly Conserved Sites in Dengue Virus NS5 Polymerase: Structural and Functional Studies.
    Arora R; Liew CW; Soh TS; Otoo DA; Seh CC; Yue K; Nilar S; Wang G; Yokokawa F; Noble CG; Chen YL; Shi PY; Lescar J; Smith TM; Benson TE; Lim SP
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32907977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598.
    Xue W; Jiao P; Liu H; Yao X
    Antiviral Res; 2014 Apr; 104():40-51. PubMed ID: 24462692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors.
    Biswal BK; Cherney MM; Wang M; Chan L; Yannopoulos CG; Bilimoria D; Nicolas O; Bedard J; James MN
    J Biol Chem; 2005 May; 280(18):18202-10. PubMed ID: 15746101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
    Herlihy KJ; Graham JP; Kumpf R; Patick AK; Duggal R; Shi ST
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3523-31. PubMed ID: 18694956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad-spectrum non-nucleoside inhibitors for caliciviruses.
    Netzler NE; Enosi Tuipulotu D; Eltahla AA; Lun JH; Ferla S; Brancale A; Urakova N; Frese M; Strive T; Mackenzie JM; White PA
    Antiviral Res; 2017 Oct; 146():65-75. PubMed ID: 28757394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydrogen/Deuterium Exchange Kinetics Demonstrate Long Range Allosteric Effects of Thumb Site 2 Inhibitors of Hepatitis C Viral RNA-dependent RNA Polymerase.
    Deredge D; Li J; Johnson KA; Wintrode PL
    J Biol Chem; 2016 May; 291(19):10078-88. PubMed ID: 27006396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors.
    Musmuca I; Caroli A; Mai A; Kaushik-Basu N; Arora P; Ragno R
    J Chem Inf Model; 2010 Apr; 50(4):662-76. PubMed ID: 20225870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An objective assessment of conformational variability in complexes of hepatitis C virus polymerase with non-nucleoside inhibitors.
    Caillet-Saguy C; Simister PC; Bressanelli S
    J Mol Biol; 2011 Dec; 414(3):370-84. PubMed ID: 22008450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation.
    Ryu K; Kim ND; Choi SI; Han CK; Yoon JH; No KT; Kim KH; Seong BL
    Bioorg Med Chem; 2009 Apr; 17(8):2975-82. PubMed ID: 19332375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition.
    Biswal BK; Wang M; Cherney MM; Chan L; Yannopoulos CG; Bilimoria D; Bedard J; James MN
    J Mol Biol; 2006 Aug; 361(1):33-45. PubMed ID: 16828488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors.
    Delang L; Vliegen I; Leyssen P; Neyts J
    J Hepatol; 2012 Jan; 56(1):41-8. PubMed ID: 21703175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1,5-benzodiazepines, a novel class of hepatitis C virus polymerase nonnucleoside inhibitors.
    Nyanguile O; Pauwels F; Van den Broeck W; Boutton CW; Quirynen L; Ivens T; van der Helm L; Vandercruyssen G; Mostmans W; Delouvroy F; Dehertogh P; Cummings MD; Bonfanti JF; Simmen KA; Raboisson P
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4420-31. PubMed ID: 18852280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of RNA binding to hepatitis C virus RNA-dependent RNA polymerase: a new mechanism for antiviral intervention.
    Ahmed-Belkacem A; Guichou JF; Brillet R; Ahnou N; Hernandez E; Pallier C; Pawlotsky JM
    Nucleic Acids Res; 2014 Aug; 42(14):9399-409. PubMed ID: 25053847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase.
    Harikishore A; Li E; Lee JJ; Cho NJ; Yoon HS
    Mol Divers; 2015 Aug; 19(3):529-39. PubMed ID: 25862642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections.
    Beaulieu PL
    Curr Opin Investig Drugs; 2007 Aug; 8(8):614-34. PubMed ID: 17668364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.